Aurobindo Pharma’s wholly owned subsidiary, Auro Pharma Ltd, has acquired the non-oncology prescription formulations business of Khandelwal Laboratories Pvt Ltd for ₹325 crore. The transaction, effective from 1 January 2026, was structured as a slump sale, meaning the business was acquired on a going-concern basis.
The acquisition includes 23 well-established brands marketed across 67 stock-keeping units (SKUs), along with nine pipeline products that are in development. The portfolio mainly comprises drugs in pain management and anti-infective therapy, two key segments in the Indian pharmaceutical market.
In the financial year 2024‑25, Khandelwal’s non-oncology business recorded a turnover of ₹113.5 crore and an EBITDA of ₹28.9 crore. It is supported by a field force of approximately 470 personnel and a distribution network covering more than 1,600 stockists across India. The acquisition, therefore, provides Aurobindo Pharma with an immediate presence in multiple therapeutic segments and strengthens its domestic reach.
Aurobindo Pharma stated that the move is aimed at broadening its prescription drug offerings while complementing its existing portfolio, particularly in pain management and anti-infective categories. The company clarified that the deal does not involve the transfer of Khandelwal Laboratories’ shares or control, and the acquired business will operate under the Auro Pharma umbrella.
The acquisition is part of Aurobindo’s broader strategy to expand its footprint in the Indian pharmaceutical market, increase its branded drug presence, and enhance overall product offerings. Analysts noted that integrating Khandelwal’s portfolio could provide synergies in sales, marketing, and distribution, allowing Aurobindo to leverage its existing infrastructure to boost growth.
Following the announcement, Aurobindo Pharma’s shares saw a modest rise, reflecting positive market sentiment about the company’s strategic expansion. Market watchers believe the deal will strengthen Aurobindo’s position in domestic prescription drugs and provide a steady revenue stream from established brands.
Also Read: Adani Power shares rises 7% as investor optimism surge